Ahn PH, et al. - Experts ascertained the maximum tolerated erlotinib dose for head and neck cancer (HNC) by initiating a phase I trial of induction cisplatin, docetaxel, 5-fluorouracil and erlotinib (TPF-E) followed by cisplatin, bevacizumab and erlotinib (PA-E) with radiotherapy (XRT) for advanced HNC. Findings suggested erlotinib along with induction TPF followed by erlotinib, cisplatin, and bevacizumab with XRT was active but toxic. Partly high rates of study withdrawal were caused by the gastrointestinal toxicities. Unexpected toxicities were caused with all doses studied in this protocol and the advancement to phase II was not recommended.